Trade Nektar Therapeutics - NKTR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0167 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.8799 |
| Open | 0.8736 |
| 1-Year Change | 69.86% |
| Day's Range | 0.8736 - 0.9303 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 0.8943 | 0.0108 | 1.22% | 0.8835 | 0.9337 | 0.8581 |
| Jan 16, 2025 | 0.8799 | -0.0135 | -1.51% | 0.8934 | 0.9012 | 0.8710 |
| Jan 15, 2025 | 0.8926 | -0.0144 | -1.59% | 0.9070 | 0.9332 | 0.8926 |
| Jan 14, 2025 | 0.8963 | -0.0589 | -6.17% | 0.9552 | 0.9624 | 0.8611 |
| Jan 13, 2025 | 0.9485 | -0.0485 | -4.86% | 0.9970 | 0.9970 | 0.9245 |
| Jan 10, 2025 | 1.0070 | -0.0900 | -8.20% | 1.0970 | 1.1070 | 1.0070 |
| Jan 8, 2025 | 1.1270 | -0.1000 | -8.15% | 1.2270 | 1.2270 | 1.1170 |
| Jan 7, 2025 | 1.1870 | 0.0300 | 2.59% | 1.1570 | 1.2370 | 1.1370 |
| Jan 6, 2025 | 1.1470 | 0.0300 | 2.69% | 1.1170 | 1.1970 | 1.1170 |
| Jan 3, 2025 | 1.1070 | 0.1718 | 18.37% | 0.9352 | 1.1470 | 0.9352 |
| Jan 2, 2025 | 0.9506 | 0.0457 | 5.05% | 0.9049 | 1.0070 | 0.9048 |
| Dec 31, 2024 | 0.9270 | 0.0200 | 2.21% | 0.9070 | 0.9512 | 0.8987 |
| Dec 30, 2024 | 0.9470 | 0.0330 | 3.61% | 0.9140 | 0.9476 | 0.9140 |
| Dec 27, 2024 | 0.9449 | 0.0412 | 4.56% | 0.9037 | 0.9509 | 0.8901 |
| Dec 26, 2024 | 0.9386 | 0.0416 | 4.64% | 0.8970 | 0.9479 | 0.8762 |
| Dec 24, 2024 | 0.8881 | -0.0089 | -0.99% | 0.8970 | 0.9057 | 0.8771 |
| Dec 23, 2024 | 0.8896 | -0.0274 | -2.99% | 0.9170 | 0.9170 | 0.8670 |
| Dec 20, 2024 | 0.9075 | 0.0072 | 0.80% | 0.9003 | 0.9394 | 0.8879 |
| Dec 19, 2024 | 0.9335 | -0.0030 | -0.32% | 0.9365 | 0.9932 | 0.8797 |
| Dec 18, 2024 | 0.8791 | -0.1379 | -13.56% | 1.0170 | 1.0270 | 0.8791 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Nektar Company profile
About Nektar Therapeutics
Nektar Therapeutics is a research-based biopharmaceutical company, which is focused on discovering and developing medicines in areas of unmet medical need. The Company's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Nektar Therapeutics revenues decreased 33% to $101.9M. Net loss increased 18% to $523.8M. Revenues reflect United States segment decrease of 84% to $10.1M. Higher net loss reflects Non-cash interest expense on liabilities increase of 56% to $47.3M (expense), Interest income and other income (expens decrease of 86% to $2.6M (income).
Equity composition
Common Stock $.0001 Par, 04/11, 300M auth., 114,073,353 issd.Insiders own 0.39% . IPO: 5/94,2.15M shares @ $7.50 by Lehman Brothers. PO 12/97, 1.725Mshares @ $24.875 by Lehman Brothers. *NOTE: 2/97, 1.8M shsissued in private placement @ $18/shs. 8/00, 2-for-1 stock split. Sr B Conv. Pfd. $0.0001 Par, 0 o/s.
| Industry: | Pharmaceuticals (NEC) |
455 Mission Bay Boulevard South
SAN FRANCISCO
CALIFORNIA 94158
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com